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ABSTRACT
Blood is a liquid tissue, in which abundant chemical factors and millions of different cells are dissolved. It is one of the most demanding sources in 
clinical and medical aspects. The issues and cost of human blood collection and storage directed this procedure toward the use of alternative blood. 
Thus, came an invention of artificial blood and blood substitutes. These alternative blood or blood substitute is a substance which is made to play 
as a substitute of erythrocytes. Thus, the main objective is to replace the normal human blood with artificial blood substitutes in the place of blood 
transfusion during surgeries and organ transfusion. Two major and focused blood substitutes in pharmaceutical aspects are perfluorocarbons and 
hemoglobin-based oxygen carriers (HBOC’s). Among these HBOCs vaguely resemble normal human blood. These blood substitutes are to allow flow 
through the blood stream to carry the oxygen and supply it to heart and other parts of the blood. They are used to fill the lost fluid volume. They are 
also called as plastic blood with iron atom as the base. They are found to serve as a good oxygen carrier. The results showed by these products are 
discussed, and they proved that they can act as a blood substitute and also they can reach the human tissue easier than erythrocytes and can control 
oxygen directly. However, these artificial blood products are being processed in research laboratories for good outcome. Their important functions 
are oxygen carrying capacity and to replace the lost blood volume in the human body. Their special features are survivability over a wider range of 
temperatures, eliminating cross matching, cost efficient, pathogen free, long shelf life, minimal side effects. Thus, artificial blood products are really a 
good alternative source which we need for replacing normal human blood.
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INTRODUCTION
The main aim of this concept is to find a source which can replace a 
human blood. Blood is a fluid which is pumped into the body by the 
pumping action of the heart and through blood vessels, they are 
circulated to all over the parts of the body. From the inhaled air, the 
arterial blood carries oxygen with the help of lungs, and the cells 
produce the waste product Co2 of this whole process or metabolism is 
carried by the venous to the lungs to get exhaled [6]. The questioning of 
why to replace a human blood is to be answered as, in present, the value 
of blood has increased and it has become one of the most demandable 
sources. In practice of surgeries and other procedures like organ 
transfusion, one can lose their body blood volume, thus the time of 
need for blood arises. In our country, the receptor’s level is much more 
increasing than donor’s level. If in case of donated blood, the patients 
should face the following complications such as same blood group and 
pathogen-free blood should be screened to check whether the blood is 
free from infectious diseases. The normal method of blood transfusion 
is mostly suggested, but it cannot meet the need of demanded blood all 
the time [20].
Blood transfusion and iron chelation therapy have improved the quality 
of life and life span to an age of around 30 years, but frequent blood 
transfusions cause progressive iron overload, which is a major clinical 
complication of the treatment [16]. Iron overload can result in multiple 
progressive organ damages grouped together under a condition called 
hemosiderosis [17]. Hence, it is to be noticed that an artificial product 
could replace the human blood and that is called as blood substitute 
(or) artificial blood [6].
BLOOD TRANSFUSION
Blood transfusion is a technique where the blood is transmitted from one 
person to other. It is also defined as injecting the blood and blood products 
to one’s circulation. This is one of the widely used methods in various 
medical and clinical fields to replace the lost components in the blood. Thus, 
in proceeding the artificial blood products on to the blood stream, the blood 
transfusion method is analyzed. Many trials were conducted with different 
blood samples, to find the common effect of treatment effect using meta-
analysis [19,23]. To considered different average percentage of donors 
which would not support the motivator goodness of fit test were used [24]. 
Furthermore, using blood plasma, platelets, and frozen blood, a supply 
chain mechanism has been invented for the supply of blood products [21]. 
During the blood transfusion of hospitalized patients, the implementation 
of restrive method strategies has proved to have the capability to decrease 
the severe health-care infections [22]. Blood transfusion not only has 
improved the lifespan but also frequent transfusions will lead to a major 
clinical complication in the treatment [18].
ARTIFICIAL BLOOD
Artificial blood is a substance made to function as a substitute of blood 
and also for the oxygen transfer throughout the body. They are also 
called as blood substitutes and artificial oxygen carriers [3]. They can 
perform the main functions such as oxygen carrying and expanding the 
blood volume. The main aim of artificial blood is to provide alternative 
way for blood transfusion. They are smaller in size around 0.08-
0.2 µ [6]. They can be in microsize, macrosize, and also in nanosize 
this comes under cellular dimensions. An unlimited types of material 
bounded to a single structure called as artificial cells. Thus, these are 
also called as nanomedicine [15]. The shape and size of the blood 
substitutes were compared with red blood cells (RBCs) and the figure 
is depicted in Fig. 1.
Need for artificial blood
Due to shortage in blood supply, the minimum stock of blood a country 
needs is 1% of its total population. In India, the total blood collection 
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recorded is 4 million units. In the case of 10% million requirements, 
it can only meet the need of 40% units. The recent reports say that the 
blood donation has increased from 4.4 million units to 9.3 million units. 
During blood transfusion from one person to another, there is a chance 
of transmission of chronic and infectious diseases like HIV, Hep B, 
Hep C, etc., and other blood-borne diseases which can be prevented/
stopped by the use of artificial blood. Mistransfusion can also occur due 
to error. The cost for collecting the blood, followed by the screening 
process, then storing it with all requirements, and administration is 
quite high for normal blood transfusion process [7].
Ideal artificial blood
Artificial blood has increased availability that would replace the demand 
of donated blood. It has most promising oxygen carrying capacity [11] 
equaling that of biological blood. It has the ability of volume expansion 
of blood inside the body. It is universal compatibility (elimination of 
cross matching). They are pathogen free and have minimal side effects. 
Ability to survive [2]. The two most promising artificial blood products 
are perfluorocarbons (PFC’s) and hemoglobin (Hb)-based oxygen 
carriers (HBOC’s).
PFCs
To modify human or animal, Hb is one of the ways to create a blood 
substitute and thus helps to solve the problem of lack of blood 
replacement; another way is to use materials better than Hb. Thus, 
fluorocarbon chemicals were invented to replace the function of Hb [6]. 
PFC’s are linear cyclic hydrocarbons of low molecular weight. In liquid 
fluorocarbons, hydrogen ions have been replaced by fluorine since they 
are neutral chemical compounds. They are sufficiently better solvents 
for carbon dioxide and oxygen to maintain the respiration process in 
animals, colorless, stable at high temperatures also, odorless, partially 
soluble, and entering weakly into chemical reactions.
PFC’s are able to release and carry a high volume of oxygen to tissue, 
and the volume of physically dissolved gas which relies on the solubility 
coefficient of the PFC’s utilized and is proportional to the gas partial 
pressure. This situation leads to increasing oxygen concentration in 
the air inspired by the patient due to several folds of increase in O2 
concentration in the emulsion of the PFC. The release of O2 to tissues is 
greatly enhanced, and extraction rates and ratios are a lot higher with 
PFCs because of weak interaction between O2 molecules, to compare 
with 25-30% of Hb PFC is able to reach 90% oxygen of its carrying [8]. 
The structure of PFC is depicted in Fig. 2.
Generations of PFCs
The different generations of PFCs along with its example are given in 
Table 1.
Perfluorocarbon emulsions
Fluorocarbon emulsion is usually well-tolerated emulsions. They often 
cause a fail in arterial blood pressure at the beginning of perfusion. 
Some of the emulsifiers are used for this process including lipids, bovine 
albumin (cow) and polyols, for example, a mixture of polyoxypropylene 
and polyoxethylene and also Plulronic F68. By the use of mechanical 
energy or ultrasound, the emulsions are produce. For ensuring easy flow 
through the capillary vascular system, the greater importance should 
be given to the selection of right degree of dispersion, gas diffusion 
capacity for obtaining the viscosity and also the time retention of the 
fluorocarbon in the circulation [4]. The structure and composition of 
perfluorocarbon emulsion are depicted in Fig. 3.
Composition of PFC-based blood substitute
The PFC-based blood substitutes can be prepared by the following 
materials, and the materials are listed in Table 2.
Advantages of PFCs
The advantage of PFC’s is they do not interact with oxygen and they 
also allow easy transportation of the oxygen to the human body. The 
supply of oxygen in plasma level has increased, and the level in plasma 
has increased. The physical parameters such as pH and temperature 
are minimized in blood circulation which makes the PFC’s the better 
alternative for the blood [5].
Benefits of PFCs
The benefits of PFC’s than biological blood are it can be stored for more 
than 1 year in a normal room temperature and the initial checking of 
blood grouping is not neccesary. This blood can even penetrate into 
small capillaries with ease allowing hem to bypass arterial blockages 
and deliver the oxygen to the most needed areas. This ease of blood 
flow is possible because of their size when compared with RBCs. It also 
has its effects on chemotherapy of radiation in tumor treatment for 
cancer patients [5].
Disadvantages of PFCs
PFC’s must be prepared as emulsions since they cannot remain in 
aqueous phase for a longer period of time. To ensure oxygenation of 
tissues, the patients must breathe at a linear rate because PFCs absorb 
oxygen passively. High requirement of fraction of inspired oxygen is 
needed [2]. Platelets count in the blood will be reduced and it causes 
flu-like symptoms. Adverse effects of PFC’s may also cause if there is 
an intake of continuous doses. It will also lead to impaired neutrophil 
function and cause allergic reactions [8].
HBOCs
Hb an obvious candidate for blood substitute that has a number of 
desirable features. The carrier has the ability to carry oxygen and 
Table 1: Generations of PFCs
S. No Generation Examples
1 1st generation Fluosol-DA™
2 2nd generation Oxyfluor™
Oxygent™
3 3rd generation Perftoran™
PHERO2™
PFCs: Perfluorocarbons







PFCs: PerfluorocarbonsFig. 1: The shape and size of blood substitutes (Jani et al., 2012)
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is countless of non-antigen complexes of erythrocyte membrane. 
According to molecular stability improvements techniques, there are 
four groups of Hb cells: Surface-modified Hb - the molecule-linked 
Hb - polymerized Hb - the Hb liposomal capsule. HBOC’s has half-life of 
18-24 hrs, which are sufficient for use in acute care. Moreover, they can 
be maintained at a temperature of 4°C for a period of 1-2 years. HBOC 
has less oxygen affinity than normal human blood [1]. The structure 
and linking of HBOC’s are depicted in Fig. 4.
Conventionally, it is recommended that for <600 ml of blood, plasma 
expanders should be used. For 600-1200 ml, RBCs products are 
essential, and blood plasma derivatives or products such as low 
platelets or whole blood transfusion are critical. Blood substitutes 
should be used as a suggestion, and complementary transfer of 
autologous or homologous should be used in combination with the 
protein.
Hb is considered as the tetramer and is linked with 2-α and 2-β 
polypeptide chains with iron heme group at the center of the molecule. 
Hb’s, as having an excellent source of blood substitute, thus it allows 
heme bonds to have high oxygen affinity [10].
Stabilization of stroma-free Hb
The initial step toward clinical study with free Hb resulted in 
nephrotoxicity. Nephrotoxicity is a toxic symptom occurred in kidney, 
and it is poisonous. The Hb used was found to have bacterial endotoxins 
as well as erythrocyte membrane stromal lipids.
To get rid of these problems, stoma-free Hbs were developed. Stroma-
free Hb has too short intravascular half-life because of tetrameric 
Hb (2-α and 2-β) dissociated into (alpha beta) dimmers. These were 
excreted in the urine after the filtration process of the kidney. During 
the purification process, the 2,3-diphosphoglycerate (DPG) is lost thus 
this stroma-free Hb has too high oxygen affinity. Hence, there is a need 
of stabilization of the Hb [7]. The structure of exact stabilization of Hb 
is depicted in Fig. 5.
In the above, Fig. 5 shows that there is a tetrameric stabilization 
taking place by intramolecular cross linking between the 2-α (or) 
2-β. After the conjugation process with the help of polyethylene 
glycol, the Hb’s molecular weight can be effectively increased. The 
polyfunctional cross-linking agents may produce polymerized Hb. 
Moreover, the liposomes can also be formed by encapsulating the 
Hb [7].
Intramolecular cross linking
The main aim of intramolecular modification is to cross-link the 2-α 
or 2-β subunits. And also to stabilize the association of the 2-α or 2-β 
dimers because the alpha or beta dimers are relatively stable [13]. The 
intramolecular cross linking of Hb is shown in Fig. 6.
3,5-dibromosalicylfumarate and nor-2-formylpyridoxal 5-phosphate 
are used as a support matric for cross-linking process. The oxygen 
affinity of Hb is reduced during cross linking, and also it prevents 
tetramer dissociation. Too high oxygen affinity of stroma-free Hb 
Fig. 2: The structure of perfluorocarbon (Mohan Krishna et al., 
2011)
Fig. 3: Structure of perfluorocarbon emulsion (Tao and 
Ghoroghchian., 2014)
Fig. 4: Structure of hemoglobin-based molecules
Fig. 5: Stabilization of free hemoglobin. (Mohankrishna et al., 
2011)
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can be fixed by the addition of DPG analogs such as pyridoxal-5’-
phosphate. To deliver more oxygen to the tissue, the more DPG is 
need in the cell. The less DPG, the less oxygen delivered to tissues. 
Pridoxylated stroma-free Hb has nearly normal oxygen affinity, for 
example, Hemopure™ [3].
Polymerized Hb
Hb oligomers are formed in the polymerization of Hb. Thus, the size of 
the molecules is increased by intermolecular cross linking. By the use 
of dialdehydes, such as glutaraldehyde and glycolaldehyde, multiple Hb 
proteins are linked together in this process [3].
The polymerization of Hb and its structure is depicted in Fig. 7.
Conjugated Hb
The process of conjugating Hb is also called as binding of Hb. To 
increase its overall size, the Hb is conjugated into a biocompatible 
polymer like as polysaccharid. To increase the molecule’s size, 
multiple polyethylene glycol chains were added to Hb protein, in 
specific case of pegylation. The conjugated tetramers from free 
tetramers are shown in Fig. 8. Once pegylated, the molecule size 
increases from 3 nm to 15 nm. To protect the molecule from renal 
excretion, conjugation of Hb with PEG takes place. The intravascular 
circulation time of HBOC can be increased by conjugating the Hb with 
macromolecules [3,14], for example, Hemospan™.
Hb vesicles (hemoglobin encapsulated vesicles)
The encapsulation process takes place when the Hb is based on the 
idea of recreating the original and natural properties of RBC in the 
absence of blood group antigens. The structure of Hb vesicle is depicted 
in Fig. 9. The hemosome is often referred to as encapsulated Hb. The 
encapsulation process involves encapsulating the Hb within lipid 
vesicles in the solution of phospholipids. The better diffusion of O2 and 
Co2 can be done by lipid membrane [3].
Recombinant Hb
From the microorganism, like Escherichia coli specially modified Hb 
may be produced, with the help of advance ADNA technology. Using 
an expression vector containing two mutant human globin genes, 
recombinant human Hb was produced in E. coli. One was fused alpha 
globins, and the other was a low oxygen affinity mutant. These products 
recombinant Hb are advanced to clinical trials, but it was completely 
stopped due to vasoconstriction and other harmful effects [3]. Some of 
the examples are depicted in Figs. 10 and 11.
The characteristics comparision between RBCs and oxygen therapeutics 
is given in Table 3.
The current status about the development process of HBOCs is given 
in Table 4.
Example of HBOCs polyheme
It is formed by extracting Hb from RBCs, and the Hb is mixed into an 
electrolyte solution after being associated into tetramer. It is compatible 
with all blood types, and it has a shelf life of approximately 12 months.
Advantages of HBOCs
They are available in larger quantities and can be sterilized by 
pasteurization process. It can be stored for long durations. Without 
typing or cross matching, it can be administered rapidly. They have 
many military applications also [7,25].
Fig. 6: Structure of intramolecular cross linking (Mohankrishna 
et al., 2011)
Fig. 7: Structure of polymerized hemoglobin. (Betts and Whittet, 
1962)
Fig. 8: Structure of conjugated hemoglobin (Mohankrishna et al., 
2011 and Shalini., 2012)
Fig. 9: Structure of hemoglobin vesicles (Shalini et al., 2012)
Fig. 10: Hemopure
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Benefits of HBOCs
It is faster and good at O2 distribution. It has long shelf life. There is 
no refrigeration needed. It is universally compatible to all receptors. 
It is one of the ready to use substances. After injection, it immediately 
offloads oxygen [3].
Disadvantages of Hb-based oxygen carriers
They have not found to be safe in humans. It has reduced circulation 
half-life. It mainly releases the free radicals into the body. It disturbs 
certain physiological structures, especially the gastrointestinal tract [7].
Adverse effects of Hb-based oxygen carriers
It causes renal effects, neurotoxicity, platelet aggregation, antigenicity, 
pancreatic, and liver enzyme elevation. They also result in 
gastrointestinal side effects, vasoactivity/hypertension, nephrotoxicity, 
coagulopathy, and immune suppression [7].
Promising techniques
Stem cells
Stem cells are capable of propagating and differentiating to multiple 
lineages which give rise to a range of many specialized cells [26]. 
Recent scientific community has started to experiment the chance of 
producing an alternative source of transfusable blood using stem cells. 
Using hematopoietic stem cells, Giarratana et al. have performed a 
study to describe a production of mature human blood cells in large 
scale (ex vivo). This represents the first directed step in this innovation. 
The content and morphology of the normal blood cells are moreover 
the same as in the blood cells produced in culture. The founders of this 
study also proved that these produced RBCs nearly have normal shelf 
life or lifespan when compared with normal RBC.
The major difficulty in this procedure is the cost of production of RBCs. 
Then, again the introduction of complex three-step method in the 
production of cells would have make the blood cells unit too expensive. 
However, this is the first study to demonstrate the possibility in large-
scale production of closely related RBC which almost resemble normal 
RBCs [2].
Biodegradable micelles
Formation of amphiphilic block copolymers by encapsulation of 
recombinant or polymerized Hb into the micellar is used to enhance 
the circulation. The diameter of this system is usually between 30 and 
100 nm. The similar hydrophobic Hb protein can be able to solubilized 
by the hydrophobic core of the micelle polymer, whereas the steric 
barrier for protein absorption is provided by water-soluble corona 
(which is usually polyethylene glycol), and the reticuloendothelial 
system (RES) provides protection from clearance [2].
Advantages of artificial blood
There is no fear of infection. It can be kept at normal room temperature 
and can be stored for the period of more than 1 year. Patients in trauma 
and other severe situations require rapid treatment. The armed 
services in medical care would get benefit from the artificial blood. The 
immediate and sudden supply of full capacity oxygen transport can be 
allowed by artificial blood. It is an alternative source for the patients 
who refuse blood transmission for cultural or religious reasons. 
Currently, the transfused blood is much more cost effective. This may 
change if the manufacturing becomes refined the cost of the artificial 
blood may fall [5].
FUTURE PERSPECTIVES
In future, the extension in research should create an artificial blood 
which with more and more minimal differences from biological blood 
Fig. 11: Oxyglobin
Table 3: Comparision of biopure’s oxygen therapeutics and RBC’s
Characteristics Biopure’s oxygen therapeutics RBC’s
Storage Room temperature (20°C–30°C) Refrigerated
Shelf life 36 months 42 days
Preparation Ready to use Testing, typing, and cross matching
Compatibility Universal Type specific
Effectiveness Immediate oxygen delivery Depend on length of storage
Purity Processed to remove infectious agents Tested and screened for infectious agents
Raw material Bovine hemoglobin Human blood
Cost 600–800 125–425
RBC’s: Red blood cells
Table 4: Current development status of HBOC’s























Maleimide PEG - human Hb
PEG conjugated bovine Hb
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and adverse effects. Since some blood substitutes still suffer from 
certain kind of limitations. Most HBOCs can no more last than 20-30 hrs. 
Thus, these are called as short-term blood transfusion. Thus, in future, 
longer lasting products which can run over a body for a longer time 
should be produced, and this development will have a wider range of 
application. Currently, some of the companies are working on it, these 
are curious questions that have to be answered for the companies who 
really interested to spend on research and production.There are many 
challenges in this aspect, but going through it will surely give this world 
a pride of science and technology. It will lead to a source to help and 
save our human kind.
CONCLUSIONS
Blood supply demand was increasing as compared to blood donation 
in all over the world. Thus, artificial blood will be ultimately useful to 
meet this demand. They can fulfill the receptor’s blood volume until 
they receive it from the donor or the option of blood transfusion is 
not acceptable. Thus, new oxygen carriers are now invented to act and 
serve as normal blood. Both inversement and intelligence are needed 
to develop the process. If the research and development process of 
artificial blood or blood substitutes has increased in their range sure, 
the world will get an unbeatable source to save human.
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